Review article · 2023 · Open access
The evolving role of investigative toxicology in the pharmaceutical industry
Nature Reviews Drug Discovery, 22(4), 317–335 · Published 13 February 2023 · DOI 10.1038/s41573-022-00633-x
In brief
“The evolving role of investigative toxicology in the pharmaceutical industry” is a 2023 review article by François Pognan and 13 co-authors, published in Nature Reviews Drug Discovery. OpenAlex counts 315 citations as of 21 November 2026, which puts it in the top 1% of works published in 2023 by citations. It is open access under a public domain licence: the full text is free to read at Nature Reviews Drug Discovery.
- Citations
- 315
- Most cited in
- 2025 (108)
- Field-weighted impact
- 12.17
- References
- 219
- Authors
- 14
Abstract
For decades, preclinical toxicology was essentially a descriptive discipline in which treatment-related effects were carefully reported and used as a basis to calculate safety margins for drug candidates. In recent years, however, technological advances have increasingly enabled researchers to gain insights into toxicity mechanisms, supporting greater understanding of species relevance and translatability to humans, prediction of safety events, mitigation of side effects and development of safety biomarkers. Consequently, investigative (or mechanistic) toxicology has been gaining momentum and is now a key capability in the pharmaceutical industry. Here, we provide an overview of the current status of the field using case studies and discuss the potential impact of ongoing technological developments, based on a survey of investigative toxicologists from 14 European-based medium-sized to large pharmaceutical companies. Investigative toxicology tools and strategies are used in pharmaceutical companies to reduce safety-related attrition in drug development. This Perspective article summarizes the key goals of investigative toxicology, highlights current approaches and discusses selected emerging technologies that have the potential to improve the current safety-testing paradigm.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Pognan, F., Beilmann, M., Boonen, H. C. M., Czich, A., Dear, G. J., Hewitt, P. G., Mow, T. J., Oinonen, T., Roth, A. B., Steger‐Hartmann, T., Valentin, J., Van Goethem, F., Weaver, R. J., & Newham, P. (2023). The evolving role of investigative toxicology in the pharmaceutical industry. Nature Reviews Drug Discovery, 22(4), 317–335. https://doi.org/10.1038/s41573-022-00633-x
MLA 9
Pognan, François, et al. “The evolving role of investigative toxicology in the pharmaceutical industry.” Nature Reviews Drug Discovery, vol. 22, no. 4, 2023, pp. 317–335. https://doi.org/10.1038/s41573-022-00633-x.
Chicago
Pognan, François, Mario Beilmann, Harrie C. M. Boonen, Andreas Czich, Gordon J. Dear, Philip G. Hewitt, Tomas Joachim Mow, et al. 2023. “The evolving role of investigative toxicology in the pharmaceutical industry.” Nature Reviews Drug Discovery 22 (4): 317–335. https://doi.org/10.1038/s41573-022-00633-x.
Harvard
Pognan, F. et al. (2023) ‘The evolving role of investigative toxicology in the pharmaceutical industry’, Nature Reviews Drug Discovery, 22(4), pp. 317–335. doi:10.1038/s41573-022-00633-x.
IEEE
F. Pognan et al., “The evolving role of investigative toxicology in the pharmaceutical industry,” Nature Reviews Drug Discovery, vol. 22, no. 4, pp. 317–335, 2023, doi: 10.1038/s41573-022-00633-x.
BibTeX
@article{pognan2023evolving,
title = {{The evolving role of investigative toxicology in the pharmaceutical industry}},
author = {Pognan, François and Beilmann, Mario and Boonen, Harrie C. M. and Czich, Andreas and Dear, Gordon J. and Hewitt, Philip G. and Mow, Tomas Joachim and Oinonen, Teija and Roth, Adrian B. and Steger‐Hartmann, Thomas and Valentin, Jean‐Pierre and Van Goethem, Freddy and Weaver, Richard John and Newham, Peter},
journal = {Nature Reviews Drug Discovery},
year = {2023},
volume = {22},
number = {4},
pages = {317--335},
doi = {10.1038/s41573-022-00633-x},
url = {https://doi.org/10.1038/s41573-022-00633-x}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 36 | |
| 2024 | 84 | |
| 2025 | 108 | |
| 2026 | 87 |
Its field-weighted citation impact is 12.17: it has been cited 12.17 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- mechanistic toxicology
- preclinical toxicology
- drug safety
- toxicity mechanisms
- translational toxicology
- safety biomarkers
- drug attrition
- pharmaceutical industry
Work with this paper
Most-cited papers in Veterinary
- Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assaysTim R. Mosmann · Journal of Immunological Methods · 1983 · 57,115 citations
- Guide for the Care and Use of Laboratory Animals: Eighth EditionNational Research Council · National Academies Press eBooks · 2011 · 16,572 citations
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningPhilip Skehan, Ritsa Storeng, Dominic A. Scudiero and 7 more · JNCI Journal of the National Cancer Institute · 1990 · 9,860 citations
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal ResearchCarol Kilkenny, William J. Browne, Innes C. Cuthill and 2 more · PLoS Biology · 2010 · 7,617 citations
- The ARRIVE guidelines 2.0: Updated guidelines for reporting animal researchNathalie Percie du Sert, Viki Hurst, Amrita Ahluwalia and 25 more · PLoS Biology · 2020 · 6,761 citations
Questions about this paper
How do I cite this paper in APA style?
Pognan, F., Beilmann, M., Boonen, H. C. M., Czich, A., Dear, G. J., Hewitt, P. G., Mow, T. J., Oinonen, T., Roth, A. B., Steger‐Hartmann, T., Valentin, J., Van Goethem, F., Weaver, R. J., & Newham, P. (2023). The evolving role of investigative toxicology in the pharmaceutical industry. Nature Reviews Drug Discovery, 22(4), 317–335. https://doi.org/10.1038/s41573-022-00633-x
How many times has this paper been cited?
315 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Nature Reviews Drug Discovery: sign in and open the PDF from this page.
Who wrote this paper?
François Pognan, Mario Beilmann, Harrie C. M. Boonen, Andreas Czich, Gordon J. Dear, Philip G. Hewitt, Tomas Joachim Mow, Teija Oinonen, Adrian B. Roth, Thomas Steger‐Hartmann, Jean‐Pierre Valentin, Freddy Van Goethem and 2 more.
What is the DOI of this paper?
10.1038/s41573-022-00633-x, permanently at https://doi.org/10.1038/s41573-022-00633-x. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.